Nautilus Biotechnology In... (NAUT)
| Bid | 0.69 |
| Market Cap | 91.37M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -70.78M |
| EPS (ttm) | -0.56 |
| PE Ratio (ttm) | -1.29 |
| Forward PE | -1.07 |
| Analyst | Hold |
| Ask | 0.83 |
| Volume | 118,768 |
| Avg. Volume (20D) | 141,366.2 |
| Open | 0.79 |
| Previous Close | 0.76 |
| Day's Range | 0.71 - 0.76 |
| 52-Week Range | 0.66 - 3.09 |
| Beta | 1.21 |
About NAUT
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington....
Analyst Forecast
According to 3 analyst ratings, the average rating for NAUT stock is "Hold." The 12-month stock price forecast is $3, which is an increase of 314.19% from the latest price.
Stock Forecasts
1 month ago · seekingalpha.com
Nautilus Biotechnology, Inc. (NAUT) Q4 2024 Earnings Call TranscriptNautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Ji-Yon Yi - Head, Investor Relations Sujal Patel - Co-Founder & Chief Exe...